News

As the field of nucleic acid therapeutics rapidly evolves, researchers require specialized building blocks to overcome biological barriers. Cosperpharma is proud to offer a premium selection of 2'-O-Methoxyethyl (MOE) Phosphoramidites. Renowned for their ability to significantly enhance nuclease resistance and binding affinity, MOE modifications are a cornerstone of successful antisense oligonucleotide (ASO) and siRNA development. Our high-purity monomers, including both standard and 5-Methyl variants, are designed to meet the rigorous demands of modern drug discovery and development.

For researchers embarking on RNA synthesis, the choice of protecting group is critical to success. Cosperpharma proudly presents our high-purity 2'-O-TBDMS Phosphoramidites. Utilizing the industry-standard tert-butyldimethylsilyl (TBDMS) protecting group, these monomers are designed to deliver exceptional performance in solid-phase oligonucleotide synthesis. Whether you are producing siRNA, CRISPR guide RNAs, or exploring structural biology, our TBDMS monomers provide the reliability and efficiency required for generating high-quality RNA transcripts.

Every successful DNA synthesis project begins with reliable, high-quality building blocks. Cosperpharma offers a comprehensive suite of standard Deoxynucleoside Phosphoramidites, available with both standard and specialized protecting groups. Whether you are conducting routine PCR, constructing complex gene assemblies, or developing cutting-edge molecular diagnostics, our meticulously synthesized monomers provide the consistent coupling efficiency and purity your workflow demands.

Cosperpharma is pleased to introduce our comprehensive line of high-purity 2'-O-Methyl (2'-OMe) Phosphoramidites. As a cornerstone modification in the development of antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and aptamers, the 2'-OMe modification is essential for enhancing nuclease resistance and binding affinity. Our premium building blocks are engineered to deliver exceptional coupling efficiency and reliable performance for your most demanding synthetic applications.

Cosperpharma is proud to highlight our premium portfolio of 2'-Fluoro Phosphoramidites. These critical building blocks are designed to meet the rigorous demands of modern oligonucleotide synthesis, offering researchers and manufacturers the reliability needed for developing next-generation therapeutics and diagnostics.

Mitapivat was developed by Agios Pharmaceuticals, an American pharmaceutical company, and is approved in the European Union and the United States as an oral treatment for hemolytic anemia and pyruvate kinase deficiency (PKD), a rare inherited disorder associated with chronic hemolytic anemia. In addition to the approved PKD indication, it is currently undergoing clinical studies for the treatment of sickle cell disease and thalassemia.